| Open Document File Size: 87,27 KBShare Result on Facebook
City New York / Paris / / Company Bayer / Genzyme Corporation / Sanofi Company / EMD Serono Inc. / / Country United States / / Event Product Issues / FDA Phase / Company Listing Change / / Facility Multiple Sclerosis Clinic of Central Texas / / IndustryTerm certified healthcare settings / healthcare / pharmaceutical / healthcare facilities / treatment of MS / any MS therapy / therapeutic solutions / healthcare providers / MS treatment / / MedicalCondition headache / inflammatory process / liver failure / urinary tract infection / rheumatoid arthritis / nausea / anaphylaxis / thrombocytopenia / alopecia / autoimmune thyroid disease / thyroid gland disorders / peripheral neuropathy / melanoma / fatigue / injury / herpes viral infection / multiple sclerosis / diarrhea / sinusitis / MS / pruritus / pneumonitis / infections / back pain / influenza / upper respiratory tract infection / hyperkalemia / abdominal pain / insomnia / antiglomerular basement membrane disease / flushing / arthralgia / nasopharyngitis / neutropenia / diabetes / vomiting / pain / Virus (HIV) infection / urticaria / diseases / lymphoproliferative disorders / fungal infection / infection / increased ALT / dizziness / thyroid cancer / rash / paresthesia / anemia / / MedicalTreatment intravenous infusion / oral therapy / contraception / dialysis / / Organization National MS Society / U.S. Food and Drug Administration / FDA / European Union / / Person Timothy Coetzee / David Meeker / Edward Fox / / / Position Research Officer / Director / President and CEO / Chief / / Product LemtradaTM / leflunomide / Rebif / Lemtrada / Aubagio® (teriflunomide) / Rebif® / United States / response / / ProvinceOrState Mississippi / / Region Central Texas / / Technology therapeutic solutions / SAN / dialysis / / URL www.genzyme.com / www.MSOnetoOne.com / /
SocialTag |
PRESS RELEASE Genzyme’s Lemtrada Approved by the FDA - Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals Paris - November 15, [removed]Sanofi and its subsidia